Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2020) Vol. 69, Iss. 9, pp. 1691-1705
Open Access | Times Cited: 581

Showing 1-25 of 581 citing articles:

Non-alcoholic fatty liver disease
Elizabeth E. Powell, Vincent Wai‐Sun Wong, Mary E. Rinella
The Lancet (2021) Vol. 397, Iss. 10290, pp. 2212-2224
Closed Access | Times Cited: 1856
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 655
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
Tracey G. Simon, Björn Roelstraete, Hamed Khalili, et al.
Gut (2020) Vol. 70, Iss. 7, pp. 1375-1382
Open Access | Times Cited: 474
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
Alessandro Mantovani, Alessandro Csermely, Graziana Petracca, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 11, pp. 903-913
Open Access | Times Cited: 395
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach
Giovanni Targher, Herbert Tilg, Christopher D. Byrne
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 7, pp. 578-588
Open Access | Times Cited: 377
Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2020) Vol. 70, Iss. 5, pp. 962-969
Open Access | Times Cited: 360
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Daniel Ferguson, Brian N. Finck
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 8, pp. 484-495
Open Access | Times Cited: 338
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Herbert Tilg, Timon E. Adolph, Michael Dudek, et al.
Nature Metabolism (2021) Vol. 3, Iss. 12, pp. 1596-1607
Closed Access | Times Cited: 303
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2020) Vol. 71, Iss. 1, pp. 156-162
Open Access | Times Cited: 262
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Romina Lomonaco, Eddison Godinez Leiva, Fernando Bril, et al.
Diabetes Care (2020) Vol. 44, Iss. 2, pp. 399-406
Open Access | Times Cited: 250
Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort
Tracey G. Simon, Björn Roelstraete, Hannes Hagström, et al.
Gut (2021) Vol. 71, Iss. 9, pp. 1867-1875
Closed Access | Times Cited: 202
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 4, pp. 367-378
Open Access | Times Cited: 171
Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons
Michael H. Le, David M. Le, Thomas C. Baez, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 287-295
Closed Access | Times Cited: 162
Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis
Heng Li, Xiao-Hua Yu, Xiang Ou, et al.
Progress in Lipid Research (2021) Vol. 83, pp. 101109-101109
Closed Access | Times Cited: 151
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
Chandani Patel Chavez, Kenneth Cusi, Sushma Kadiyala
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 1, pp. 29-38
Open Access | Times Cited: 120
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease
Diana Barb, Enrico Repetto, Michael Edward Stokes, et al.
Obesity (2021) Vol. 29, Iss. 11, pp. 1950-1960
Open Access | Times Cited: 113
Organoids: The current status and biomedical applications
Siqi Yang, Hai‐Jie Hu, Heng‐Chung Kung, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 104
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
Xiaodong Zhou, Jingjing Cai, Giovanni Targher, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 100
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne, et al.
Hepatology International (2023) Vol. 17, Iss. 4, pp. 773-791
Open Access | Times Cited: 91
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors
Emir Muzurović, Carol Chiung‐Hui Peng, Matthew J. Belanger, et al.
Hypertension (2022) Vol. 79, Iss. 7, pp. 1319-1326
Closed Access | Times Cited: 89
Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
Christoph Grander, Felix Grabherr, Herbert Tilg
Cardiovascular Research (2023) Vol. 119, Iss. 9, pp. 1787-1798
Open Access | Times Cited: 78
Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review
Narjes Nasiri‐Ansari, Θεόδωρος Ανδρουτσάκος, Christina‐Maria Flessa, et al.
Cells (2022) Vol. 11, Iss. 16, pp. 2511-2511
Open Access | Times Cited: 76
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Julian M. Yabut, Daniel J. Drucker
Endocrine Reviews (2022) Vol. 44, Iss. 1, pp. 14-32
Open Access | Times Cited: 75
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease
Dan‐Qin Sun, Giovanni Targher, Christopher D. Byrne, et al.
HepatoBiliary Surgery and Nutrition (2023) Vol. 12, Iss. 3, pp. 386-403
Open Access | Times Cited: 59
Predictive Role of Neutrophil-Percentage-to-Albumin Ratio (NPAR) in Nonalcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Nondiabetic US Adults: Evidence from NHANES 2017–2018
Chi-Feng Liu, Li-Wei Chien
Nutrients (2023) Vol. 15, Iss. 8, pp. 1892-1892
Open Access | Times Cited: 52
Page 1 - Next Page

Scroll to top